Actively Recruiting
Endosonography-guided Gallbladder Drainage vs Non-endoscopic Treatment in Inoperable Acute Cholecystitis
Led by Fundacion Miguel Servet · Updated on 2023-01-27
100
Participants Needed
1
Research Sites
195 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In this project the investigators propose to carry out a clinical trial that compares non-endoscopic treatment of cholecystitis with antibiotics versus endoscopic drainage in non-operable acute cholecystitism (AC), especially focused on the rate of subsequent EBP and recurrence of AC, as well as the impact on the quality of life, also exploring the costs. The ultimate goal of this project is to generate knowledge and scientific evidence that makes it easier for health professionals to choose the most appropriate strategy for non-operable patients with lithiasic AC. Ourworking hypothesis is that endoscopic treatment (EUS-GBD) will significantly reduce the number of EBP compared to non-endoscopic treatment in patients with non-operable lithiasic AC.
CONDITIONS
Official Title
Endosonography-guided Gallbladder Drainage vs Non-endoscopic Treatment in Inoperable Acute Cholecystitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient older than 18 years.
- Definitive diagnosis of acute lithiasic cholecystitis according to GP Tokyo 2018 criteria.
- Surgical decision of inoperable patient due to age �3e�3d 80 years, ASA III or more, Charlson Comorbidity Index > 5, Karnofsky < 50, or patient's choice not to have surgery.
- Signed informed consent for study participation.
You will not qualify if you...
- Operable acute cholecystitis.
- Patient refusal to participate in the study.
- Altered gastrointestinal anatomy from previous hepatobiliary or upper GI surgery.
- Presence of ascites.
- Unable to tolerate sedation or with contraindications to endoscopy.
- Decompensated cirrhosis, portal hypertension, or gastric varices.
- Uncorrectable coagulopathy with INR > 1.5 or thrombocytopenia < 50,000/mm3.
- Other diagnoses on admission such as choledocholithiasis, liver abscess, acute pancreatitis, or biliopancreatic tumors.
- Hemodynamic instability.
- Baseline ECOG performance status of 4 or higher.
- Life expectancy less than 6 months.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital Universitario de Navarra
Pamplona, Navarre, Spain, 31008
Actively Recruiting
Research Team
J
Jesús JU Urmán, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here